Skip to content

Study on the intestinal microflora characteristics and TCM syndromes of patients with hepatocellular carcinoma complicated with intestinal dysfunction

Study on the intestinal microflora characteristics and TCM syndromes of patients with hepatocellular carcinoma complicated with intestinal dysfunction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200005950
Enrollment
Unknown
Registered
2022-04-29
Start date
2022-04-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hepatic carcinoma

Interventions

trail group:none
control group:none

Sponsors

Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with hepatocellular carcinoma complicated with intestinal dysfunction. (2) A history of hepatitis B cirrhosis. (3) Child-Pugh=8, ascites quantity was grade 1. (4) Aged 18-75, male or female, out-patient or inpatient in our department. (5) The course of disease is more than 6 months, and the patient has persistent abdominal discomfort or pain in the last 3 months, accompanied by at least 2 of the following characteristics: 1.Abnormal frequency of defecation (defecation >3 times a day or <3 times a week); 2.Abnormal fecal traits (lumpy/hard or watery stools); 3.abnormal fecal discharge process (effort, urgency, sense of exhaustion); 4.Mucinous stool; 5.Gastrointestinal flatulence or abdominal distension.

Exclusion criteria

Exclusion criteria: (1) The patient's Child-Pugh was C, or the BCLC stage was D. (2) The patient had moderate or large ascites or had upper gastrointestinal bleeding. (3) Used gastric acid inhibitors (proton pump inhibitors and H2 receptor antagonists), microbial agents, antibacterial drugs, metformin or non-absorbable disaccharides (such as lactilose) that affect intestinal flora, or targeted therapy drugs such as sorafenib, ramvaritinib and anlotinib within the last 4 weeks. (4) Patients with rheumatic immune diseases or systemic inflammation such as bacterial infection in the last 3 months. (5) White blood cells detected by routine stool microscopy were > 3 / high magnification field.

Design outcomes

Primary

MeasureTime frame
the intestinal microflora characteristics;

Countries

China

Contacts

Public ContactCheng Binbin

Changhai Hospital

cbb8202@smmu.edu.cn13916943770

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026